Analysts Offer Predictions for Bausch + Lomb Q1 Earnings

Bausch + Lomb Corporation (NYSE:BLCO) – HC Wainwright issued their Q1 2026 earnings per share estimates for Bausch + Lomb in a research note issued on Monday, February 23rd. HC Wainwright analyst Y. Chen expects that the company will post earnings of $0.14 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.74 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.27 EPS and FY2026 earnings at $0.78 EPS.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, February 18th. The company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by ($0.03). Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. The company had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.38 billion. During the same period last year, the firm earned $0.25 EPS. The business’s quarterly revenue was up 9.8% compared to the same quarter last year.

A number of other research firms have also recently commented on BLCO. Barclays boosted their price objective on Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Citigroup boosted their price target on shares of Bausch + Lomb from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $18.00 price objective on shares of Bausch + Lomb in a report on Thursday, February 19th. JPMorgan Chase & Co. boosted their target price on shares of Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Finally, Evercore set a $18.00 price objective on Bausch + Lomb and gave the stock an “in-line” rating in a report on Monday, January 5th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $18.25.

Bausch + Lomb Stock Performance

BLCO opened at $18.43 on Tuesday. The stock has a market cap of $6.53 billion, a P/E ratio of -18.07, a P/E/G ratio of 0.74 and a beta of 0.61. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.55 and a quick ratio of 1.04. The firm has a fifty day moving average price of $17.11 and a 200 day moving average price of $15.94. Bausch + Lomb has a 1 year low of $10.45 and a 1 year high of $18.64.

Hedge Funds Weigh In On Bausch + Lomb

A number of institutional investors have recently bought and sold shares of the company. Oaktree Capital Management LP acquired a new position in Bausch + Lomb during the 2nd quarter worth about $32,801,000. Handelsbanken Fonder AB acquired a new stake in shares of Bausch + Lomb during the second quarter worth about $202,000. Goldentree Asset Management LP boosted its stake in shares of Bausch + Lomb by 14.9% in the second quarter. Goldentree Asset Management LP now owns 2,583,185 shares of the company’s stock valued at $33,524,000 after purchasing an additional 334,916 shares during the period. Kazazian Asset Management LLC acquired a new position in shares of Bausch + Lomb in the second quarter valued at approximately $722,000. Finally, Fountainhead AM LLC acquired a new position in shares of Bausch + Lomb in the second quarter valued at approximately $193,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.